CheckMate-227 Three-year follow-up data confirm that Odivo (Navuriu monoantigen) combined with Ipitaph monoantigen for first-line metastatic non-small cell lung cancer patients with long-term and long-term survival benefits

On May 13, 2020, Shiguibao of Boxei announced the results of a three-year follow-up to Part 1 of Phase III Clinical Study CheckMate 227The results showed that Odivo's combination of Epiwood monoantigen treatment metastatic non-small cell lung cancer (NSCLC) could continuously improve the total survival (OS) and other efficacy indicators in patientsWith a median follow-up time of more than 3 years (43.1 months), Odivo's combined ipitano resistance provided a sustainable survival benefit to patients (PD-L1 to 1%) compared to chemotherapy aloneIn this treatment group, the three-year OS rate was 33% for patients treated with Odyvo's combined ipitaph monoantigen, compared with 22% in the chemotherapy groupOdivo's combined ipitano resistance was shown to delay the progression or death of such patients, with a 3-year progression-free survival rate (PFS) of 18 percent, compared with 4 percent in the chemotherapy group38 percent of patients who responded to the acolynitior of Odivo and had PD-L1 to 1 percent continued to respond three years after the start of the response, compared with only 4 percent in the chemotherapy groupFor patients who had stopped treatment after two years of combined treatment, the researchers also observed a continuous responseIn addition, in the analysis of OS by response, the researchers observed that 70 percent of patients in the Odivo-Ipitanotherapy group who had full or partial remission within six months were still alive after three years, compared with 39% in the chemotherapy groupin exploratory analysis of 1% of patients with PD-L1, the 3-year OS rate was 34% in patients in the Odivo itimu monoantigen group and 15% in the chemotherapy group (HR: 0.64; 95% CI: 0.51 to 0.81)In addition, the proportion of patients who survived and did not progress since the randomization group was 13% in the Odivo ipitanotherapy group and 2% in the chemotherapy group, and the proportion of patients who responded after the onset of treatment and still produced a response three years later: 34% in the Odivo United Ipitus monoantigen group and 0% in the chemotherapy groupthe safety of Odivo's combined Ipitaph monoantigen treatment was consistent with previously reported results of non-small cell lung cancer studies, with no new safety signals observedThe results of the study (summary s.9500) will be presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting"Non-small cell lung cancer is a complex and invasive disease, and while treatment sprees have come a long way in recent years, there is still a need for treatment options that can potentially benefit them in the long term," said DrSuresh SRamalingam, associate director of the Winship Cancer Institute at Emory University and associate director of the Emory School of MedicineThe three-year study of CheckMate 227 has shown that, as a first-line treatment for non-small cell lung cancer, Navuliyu monoantigen sylfiatosis can provide a lasting survival benefit to patients The research data confirm the established scientific theory that PD-1 and CTLA-4 dual immunotherapy promise sapathies to provide a deep and long-lasting response to specific patients "
follow-up data for at least 3 years showed that the benefits of Odiva's combined ipitaph monosacis were better than Odivo's monodrugation in patients with PD-L1, while in 1% of patients with PD-L1, the therapeutic benefits from the Odiva-Ipimu monoantigen were better than the combination of Odivandandand and chemotherapy "We have achieved long-term total survival results in a number of Phase III clinical studies of Theodiwota," said Dr Nick Botwood, Vice President of Clinical Development, , "Including three types of advanced non-small cell lung cancer, melanoma and renal cell carcinoma At the same time, we have made positive progress in critical trials of first-line plethora and second-line non-small cell lung cancer After reaching the end of the primary study of total survival in PD-L1 expression patients, we expect the U.S Food and Drug Administration to approve Odivo's combination of epibusa for treatment of first-line non-small cell lung cancer patients, which will be the fifth indication approved for this combination The three-year follow-up data for Part 1 of CheckMate 227 are further evidence that combination of dual immunotherapy can deliver lasting benefits to patients Odivo is a unique combination of two immunocheckpoint inhibitors with potential synergies for two different checkpoints (PD-1 and CTLA-4) to help eliminate tumor cells: Epiwood monoresist helps activate and multiply T cells, while Odivo helps existing T-cells detect tumors Some T-cells activated by Epima can differentiate into memory T-cells, which is expected to achieve a long-term immune response Note: Ipitano not yet listed in China
source: MedSci